Not a Miracle Test: IHPME Health Economics Expert Explains True Costs of Genetic Testing

April 25, 2018

Share Post

From 23 and Me and Ancestry DNA to research laboratories, genome sequencing has become more widely available, and many would have you believe it’s an affordable option for just about anyone to get themselves tested for the risk of a variety of diseases, from various cancers to Alzheimer’s.

“On the one hand it’s great to see the public becoming more aware of options for genetic testing, but one downside is that people start to think of sequencing as a “miracle” test, and that we should screen for every possible future disease no matter what the cost,” said Wendy Ungar a professor of health economics at U of T’s Institute of Health Policy, Management and Evaluation.

The technology has advanced rapidly in recent years, and policy has yet to keep up. Should all genetic testing be covered by our provincial health plans or just a few?  Health care systems like Ontario’s have constrained budgets, so understanding what types or topics of genetic testing are cost-effective, is of major interest to the Ministry of Health and Long-term Care (MOHLTC).

3d render illustration DNA structure in blue background.
Photo courtesy of iStock.

“We have to look at what makes sense in terms of value, and not simply whether a test costs $100 or even $1000,” said Ungar, who is also Director of Technology Assessment at Sick Kids (TASK). “Is the test supported by scientific and economic evidence and will it truly help patients and clinicians in terms of treating or preventing disease? These are the types of questions we need to consider, not just the dollar amount.”

Ungar is Chair of Health Quality Ontario’s Ontario Genetics Advisory Committee, also known as OGAC, where she and her colleagues are working to help the province and the ministry gain a better understanding of the value of different genetic tests and how or if they should be funded.

“We prioritize different topics of testing, such as carrier screening and non-invasive prenatal testing among others, and look at where there is the most need or demand,” said Ungar. “Once these tests are prioritized, a health technology assessment and budget impact analysis are conducted and the results are deliberated by the committee.”

One topic of testing currently under deliberation is non-invasive prenatal screening, or NIPT. “A pregnant woman actually has fetal DNA circulating in her bloodstream, so a simple blood draw can be analyzed to look at whether certain conditions may be present in the fetus,” said Ungar.

This test can identify chromosomal abnormalities related to trisomies such as Down syndrome and is currently only funded for women who are pregnant and considered high risk such as those over the age of 40 or those with a family history of trisomies and other chromosomal abnormalities, but it is not publicly funded for everyone.

“Amniocentesis and chorionic villus sampling are other testing options available, but they pose a risk to the fetus and the pregnancy because they are much more invasive,” said Ungar.

The committee also needs to consider the care pathway for prenatal care and how it might change if it the decision was made to make the test available to all pregnant women.

Profile of Wendy Ungar speaking with blue screen background
Wendy Ungar

“At what stage of care should we offer the test? At the first ultrasound or as part of the first blood test? These are further questions we are taking into account as part of the review,” said Ungar. A funding recommendation for NIPT is expected to be posted to the HQO web site for public feedback in May.

Watch Wendy Ungar’s Genome Discussion at the Royal Canadian Institute of Science

Should we be more cautious about newer generations of genetic testing such as genome sequencing?

Ungar explains that patients can have several potentially pathogenic variants appear that are not related to the original reason for undergoing a genetic test. These variants can show risks for breast cancer or colon cancer or even Huntington’s disease, and once disclosed to the patient, they can trigger further costs to the health system as patients seek care from specialists to reduce their risks for such diseases.

“It is not just a single test, a single result, or a single patient — there are a whole host of cascading effects that we need to consider, including effects on the patients themselves and their family members.”

Related News

Image of attendees at the Moonshot 2023 event

Moonshot 2023: An Evening of Celebration, Learning, and Community Building 

December 7, 2023

Awards / Faculty / Students

Read More
Valeria Rac

Dr. Valeria Rac named Canada Research Chair in Health System and Technology Evaluation

December 6, 2023

Faculty / Research

Read More
Image of Class of 2024 from the QIPS program

Speaking the same language: QIPS program develops and connects change makers and innovators across the health system

October 2, 2023

Education / Faculty / Students

Read More
Headshots of the 2023 Vanier Winners

2023 Vanier Canada Graduate Scholarships

August 29, 2023

Awards / Students

Read More

OHT Impact Fellows help build a learning health system in Ontario

August 14, 2023


Read More

IHPME alumna appointed Sunnybrook Health Sciences Centre’s newest vice-president

July 31, 2023


Read More

Sign up for IHPME Connect.

Keep up to date with IHPME’s News & Research, Events & Program, Recognition, e-newsletter.

* indicates required

Get in Contact


Email Address: ihpme.communications@​

Manages all IHPME-wide communications and marketing initiatives, including events and announcements.